2:43 PM
 | 
Nov 28, 2018
 |  BC Extra  |  Financial News

Follow-on roundup: Acadia raises $275M, Rocket pockets $55M

CNS company Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) and gene therapy company Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) each priced follow-ons late Tuesday, raising $275 million and $55 million, respectively.

Acadia markets Nuplazid pimavanserin, a small molecule serotonin receptor 2A (5-HT2A; HT2RA) inverse agonist approved to treat...

Read the full 193 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >